Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Completed 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Prostatic Neoplasms 3Neoplasms, Plasma Cell 3Multiple Myeloma 3Sarcoma 1Osteosarcoma 1

Interventions

Dexamethasone 363Bortezomib 232Lenalidomide 202Cyclophosphamide 174Melphalan 154Calcium Dobesilate 107Peripheral Blood Stem Cell Transplantation 92fludarabine phosphate 84Thalidomide 81Filgrastim 71carfilzomib 68pomalidomide 66Granulocyte Colony-Stimulating Factor 60Mycophenolic Acid 59Busulfan 57daratumumab 55Whole-Body Irradiation 54Tacrolimus 51ixazomib 50Prednisone 50Cyclosporine 49fludarabine 46Antilymphocyte Serum 35Etoposide 30dexamethasone acetate 29Methotrexate 29plerixafor 27Radiotherapy 26Doxorubicin 26dexamethasone 21-phosphate 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Multiple Myeloma × samarium Sm-153 lexidronam × Clear all
NCT00316940 2013-09-20

Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 1 Completed
36 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00602706 2011-05-16

Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Mayo Clinic

Phase 1/2 Completed
76 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00478075 2011-05-11

Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Mayo Clinic

Phase 1/2 Completed
50 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡